Predict your next investment

Corporation
HEALTHCARE | Biotechnology
acadia-pharm.com

See what CB Insights has to offer

Founded Year

1993

Stage

PIPE | IPO

Total Raised

$47.7M

Market Cap

3.18B

Stock Price

18.79

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals, formerly Recptor Technologies, is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company has five drug programs in clinical and preclinical development. ACADIA's three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease currently in Phase II clinical trials, and ACP-104 and ACP-103, both for the treatment of schizophrenia. The company has two preclinical programs for the development of drug candidates for neuropathic pain and glaucoma in collaboration with Allergan.

ACADIA Pharmaceuticals Headquarter Location

3911 Sorrento Valley Boulevard

San Diego, California, 92121,

United States

858-558-2871

Latest ACADIA Pharmaceuticals News

Acadia teams with storytelling giant StoryCorps to record Parkinson’s stories — and erase stigma

Nov 17, 2021

Beth Snyder Bulik Senior Editor Acadia Pharmaceuticals is putting the power of storytelling to work for Parkinson’s disease. While storytelling in general is often used in pharma marketing to help explain the realities of health conditions, Acadia is teaming up with the storytelling powerhouse StoryCorps for the new campaign . Called “Yours, Truly,” the work centers on pairs of people in poignant conversations relaying the stories of their own or their loved ones’ Parkinson’s experience. Keep reading Endpoints with a free subscription Unlock this story instantly and join 123,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Zachary Brennan Senior Editor The House Energy & Commerce Committee began marking up a dozen bills on Wednesday morning including one that would require the FDA to craft a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases. Rare neurodegenerative diseases, like amyotrophic lateral sclerosis or ALS, have been historically very difficult to treat. But this bipartisan bill, introduced by Rep. Mike Quigley (D-IL), will provide $100 million for each of fiscal years 2022 through 2026 to help HHS award grants to facilitate access to investigational drugs that diagnose or treat ALS. Read More Jason Mast Editor A few weeks after Jennifer Doudna introduced CRISPR/Cas9 genome editing to the world, one of her old students decided to take the central part of the biology-altering invention and kill it. CRISPR/Cas9, as the name implies, is a two-part system: a string of letters called a guide RNA, that says where to cut the DNA. And an enzyme, Cas9, that does the cutting. Often compared to molecular scissors, it was the first system that allowed researchers to cut DNA with ease and precision, promising potential cures for genetic diseases such as sickle cell and cystic fibrosis. Premium subscription required Zachary Brennan Senior Editor Although sales of Biogen’s expensive new Alzheimer’s drug have been anemic since the approval in June, the prospect of CMS eventually paying for it opens up a billion-dollar can of worms, and already has the agency defending some premium and deductible increases for seniors. CMS explained late Friday that Medicare Part B will have to increase its standard monthly premium — from $148.50 in 2021 to $170.10 in 2022 — in part because of the massive spending that could occur should the agency sign off on a national coverage decision for the drug, known as Aduhelm, and its $56,000 annual price tag next year. Keep reading Endpoints with a free subscription Unlock this story instantly and join 123,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Zachary Brennan Senior Editor Reps. Fred Upton (R-MI) and Diana DeGette (D-CO) on Tuesday unveiled the second iteration of their mammoth 21st Century Cures Act, a wide-ranging, mostly pro-pharma law signed by former President Obama that pushed the FDA in certain directions on real-world data and other hot button issues. This time around there’s a provision to fund a $6.5 billion (on par with Biden’s request) research center at NIH to speed new treatments and make riskier investments. Similar to DARPA, the new NIH division to be known as ARPA-H, would be run by a small group of program managers with more latitude to pursue high-risk, high-reward projects. Premium subscription required Kyle Blankenship Managing Editor The US Securities and Exchange Commission has launched a probe into claims that Cassava Sciences, an Austin-based drug developer, manipulated data key to its case for its experimental Alzheimer’s drug simufilam, the Wall Street Journal reported Wednesday. The report comes just two days after Cassava in an SEC filing revealed that “certain government agencies” had asked the biotech for documentation. It wasn’t clear which agencies were inquiring or what information they sought, and Cassava went out of its way to say the requests weren’t accusations of wrongdoing. Keep reading Endpoints with a free subscription Unlock this story instantly and join 123,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

ACADIA Pharmaceuticals Patents

ACADIA Pharmaceuticals has filed 67 patents.

The 3 most popular patent topics include:

  • Piperidines
  • Fluoroarenes
  • Piperazines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/10/2020

11/2/2021

Analgesics, Amines, Piperidines, Anticonvulsants, Calcium channel blockers

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/10/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/2/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Analgesics, Amines, Piperidines, Anticonvulsants, Calcium channel blockers

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

ACADIA Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ACADIA Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.